Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 14;13(5):1670.
doi: 10.3390/nu13051670.

The Importance of Phosphate Control in Chronic Kidney Disease

Ken Tsuchiya  1 , Taro Akihisa  2
Affiliations
Review

The Importance of Phosphate Control in Chronic Kidney Disease

Ken Tsuchiya et al. Nutrients. .

Abstract

A series of problems including osteopathy, abnormal serum data, and vascular calcification associated with chronic kidney disease (CKD) are now collectively called CKD-mineral bone disease (CKD-MBD). The pathophysiology of CKD-MBD is becoming clear with the emerging of αKlotho, originally identified as a progeria-causing protein, and bone-derived phosphaturic fibroblast growth factor 23 (FGF23) as associated factors. Meanwhile, compared with calcium and parathyroid hormone, which have long been linked with CKD-MBD, phosphate is now attracting more attention because of its association with complications and outcomes. Incidentally, as the pivotal roles of FGF23 and αKlotho in phosphate metabolism have been unveiled, how phosphate metabolism and hyperphosphatemia are involved in CKD-MBD and how they can be clinically treated have become of great interest. Thus, the aim of this review is reconsider CKD-MBD from the viewpoint of phosphorus, its involvement in the pathophysiology, causing complications, therapeutic approach based on the clinical evidence, and clarifying the importance of phosphorus management.

Keywords: CKD-MBD; FGF23; aKlotho; phosphate-binder.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative sections immunohistochemically stained for α-SMA in the renal tubules in the reduced Klotho expression mice treated by unilateral ureteral obstruction. Renal fibrosis was induced by unilateral ureteral obstruction (UUO) in mice with reduced αKlotho expression αkl (+/−) mice and compared them with wild-type mice. The UUO kidneys from αkl (+/−) mice expressed significantly higher levels of fibrosis marker, α-smooth muscle actin (α-SMA), than those from wild-type αkl (+/+) mice. Adapted from reference [29].
Figure 2
Figure 2
Changes in Klotho protein, FGF-23, PTH, 1,25(OH)2D3, and phosphate as CKD progresses. When Klotho expression first decreases, FGF-23 increases, lowering circulating 1,25(OH)2D3, which depresses Klotho expression further and increases PTH expression. Increased PTH induces further FGF-23 increases, causing large decreases in 1,25(OH)2D3 and large increases in PTH. This cycle results in hyperphosphatemia in late stages of CKD. CKD, chronic kidney disease; FGF-23, fibroblast growth factor-23; PTH, parathyroid hormone. Adapted from reference [38].
See this image and copyright information in PMC

References

    1. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51. doi: 10.1038/36285. - DOI - PubMed
    1. ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000;26:345–348. doi: 10.1038/81664. - DOI - PubMed
    1. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., Takeuchi Y., Fujita T., Fukumoto S., Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA. 2001;98:6500–6505. doi: 10.1073/pnas.101545198. - DOI - PMC - PubMed
    1. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., Baum M.G., Schiavi S., Hu M.C., Moe O.W., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006;281:6120–6123. doi: 10.1074/jbc.C500457200. - DOI - PMC - PubMed
    1. Jacquillet G., Unwin R.J. Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi) Pflug. Arch. 2019;471:83–98. doi: 10.1007/s00424-018-2231-z. - DOI - PMC - PubMed